Severe gastrointestinal disease in very early systemic sclerosis is associated with early mortality

OBJECTIVES To examine the incidence, predictors and outcomes associated with severe gastrointestinal (GI) disease in a large inception SSc cohort. METHODS SSc subjects with <2 years of disease duration were identified from two multicentre cohorts. Severe GI disease was defined as: malabsorption, hyperalimentation, pseudo-obstruction and/or ⩾10% weight loss in association with the use of antibiotics for bacterial overgrowth or oesophageal stricture. Kaplan-Meier, multivariate logistic regression and Cox proportional hazard analyses were performed to determine the cumulative incidence rate, independent clinical correlates and mortality rate associated with severe GI disease. A longitudinal mixed model was used to assess the impact of severe GI disease on the Short Form Health Survey. RESULTS In this inception SSc cohort, the probability of developing severe GI disease was estimated at 9.1% at 2 years and 16.0% at 4 years. In multivariate analysis, severe GI disease was associated with inflammatory myositis (odds ratio 4.68, 95% CI 1.65, 13.24), telangiectasias (odds ratio 2.45, 95% CI 1.19, 5.04) and modified Rodnan skin score (odds ratio 1.03, 95% CI 1.01, 1.07). Severe GI disease was associated with a >2-fold increase in the risk of death (hazard ratio 2.27, 95% CI 1.27, 4.09) and worse health-related quality of life [Short Form Health Survey physical (β = -2.37, P = 0.02) and mental (β = -2.86, P = 0.01) component summary scores]. CONCLUSION Severe GI disease is common in early SSc and is associated with significant morbidity and increased mortality. More research is needed to understand, prevent and mitigate severe GI disease in SSc.

[1]  M. Gosho,et al.  Analysis of an incomplete longitudinal composite variable using a marginalized random effects model and multiple imputation , 2018, Statistical methods in medical research.

[2]  D. Mar,et al.  Gastrointestinal and Hepatic Disease in Systemic Sclerosis. , 2018, Rheumatic diseases clinics of North America.

[3]  Per B. Brockhoff,et al.  lmerTest Package: Tests in Linear Mixed Effects Models , 2017 .

[4]  H. Uchi,et al.  Pathogenesis of systemic sclerosis—current concept and emerging treatments , 2017, Immunologic research.

[5]  M. Hudson,et al.  Early Mortality in a Multinational Systemic Sclerosis Inception Cohort , 2017, Arthritis & rheumatology.

[6]  S. Jimenez,et al.  Review article: pathogenesis and clinical manifestations of gastrointestinal involvement in systemic sclerosis , 2017, Alimentary pharmacology & therapeutics.

[7]  J. Varga,et al.  Impaired quality of life in systemic sclerosis and patient perception of the disease: A large international survey. , 2016, Seminars in arthritis and rheumatism.

[8]  F. Mendoza,et al.  Role of muscarinic-3 receptor antibody in systemic sclerosis: correlation with disease duration and effects of IVIG. , 2016, American journal of physiology. Gastrointestinal and liver physiology.

[9]  G. Riemekasten,et al.  Risk factors for severity and manifestations in systemic sclerosis and prediction of disease course , 2016, Expert review of clinical immunology.

[10]  Y. Allanore,et al.  Skin Telangiectasia and the Identification of a Subset of Systemic Sclerosis Patients With Severe Vascular Disease , 2015, Arthritis care & research.

[11]  M. Hudson,et al.  Thinking outside the box--The associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect. , 2015, Seminars in arthritis and rheumatism.

[12]  M. Hsieh,et al.  Reduced incidence of Crohn’s disease in systemic sclerosis: a nationwide population study , 2015, BMC Musculoskeletal Disorders.

[13]  M. Hudson,et al.  2013 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Systemic Sclerosis Outperform the 1980 Criteria: Data From the Canadian Scleroderma Research Group , 2015, Arthritis care & research.

[14]  M. Hudson,et al.  Systemic Sclerosis Sine Scleroderma: A Multicenter Study of 1417 Subjects , 2014, The Journal of Rheumatology.

[15]  X. Corbella,et al.  Mortality and survival in systemic sclerosis: systematic review and meta-analysis. , 2014, Seminars in arthritis and rheumatism.

[16]  D. Bates,et al.  Fitting Linear Mixed-Effects Models Using lme4 , 2014, 1406.5823.

[17]  C. Bascoul-Mollevi,et al.  Comparison of three longitudinal analysis models for the health-related quality of life in oncology: a simulation study , 2014, Health and Quality of Life Outcomes.

[18]  M. Mayes,et al.  An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative , 2013 .

[19]  M. Baron,et al.  The 15% Rule in Scleroderma: The Frequency of Severe Organ Complications in Systemic Sclerosis. A Systematic Review , 2013, The Journal of Rheumatology.

[20]  Bodo Winter,et al.  Linear models and linear mixed effects models in R with linguistic applications , 2013, ArXiv.

[21]  J. Gordon,et al.  Low prevalence of coeliac disease in patients with systemic sclerosis: a cross-sectional study of a registry cohort. , 2013, Rheumatology.

[22]  N. McHugh,et al.  Predictors of health-related quality of life and fatigue in systemic sclerosis: evaluation of the EuroQol-5D and FACIT-F assessment tools , 2012, Clinical Rheumatology.

[23]  M. Omair,et al.  Effect of Gastrointestinal Manifestations on Quality of Life in 87 Consecutive Patients with Systemic Sclerosis , 2012, The Journal of Rheumatology.

[24]  R. Steele,et al.  Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis , 2012, Arthritis care & research.

[25]  M. Baron,et al.  Gastrointestinal Manifestations of Scleroderma: Recent Progress in Evaluation, Pathogenesis, and Management , 2012, Current Rheumatology Reports.

[26]  S. Laurberg,et al.  Faecal incontinence in patients with systemic sclerosis: is an impaired internal anal sphincter the only cause? , 2011, Scandinavian journal of rheumatology.

[27]  T. Skare,et al.  Celiac disease screening in patients with scleroderma. , 2011, Arquivos de gastroenterologia.

[28]  E. Feierl,et al.  Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database , 2010, Annals of the rheumatic diseases.

[29]  R. Adams,et al.  New Australian population scoring coefficients for the old version of the SF-36 and SF-12 health status questionnaires , 2010, Quality of Life Research.

[30]  M. Majdan,et al.  Gastrointestinal involvement in patients with systemic sclerosis. , 2010, Polskie Archiwum Medycyny Wewnetrznej.

[31]  Ami A. Shah,et al.  Telangiectases in Scleroderma: A Potential Clinical Marker of Pulmonary Arterial Hypertension , 2010, The Journal of Rheumatology.

[32]  A. Forbes,et al.  Gastrointestinal complications: the most frequent internal complications of systemic sclerosis. , 2009, Rheumatology.

[33]  R. Domsic,et al.  Gastrointestinal Manifestations of Systemic Sclerosis , 2008, Digestive Diseases and Sciences.

[34]  Alan C. Wilson,et al.  Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization. , 2008, The Journal of rheumatology.

[35]  N. Kamatani,et al.  Characteristics of patients with early systemic sclerosis and severe gastrointestinal tract involvement. , 2007, The Journal of rheumatology.

[36]  T. Krieg,et al.  Skin disease: a cardinal feature of systemic sclerosis. , 2006, Rheumatology.

[37]  C. Schentag,et al.  Quality of life and functional status in systemic sclerosis compared to other rheumatic diseases. , 2006, The Journal of rheumatology.

[38]  R. Hays,et al.  Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. , 2005, The Journal of rheumatology.

[39]  T. Medsger,et al.  Criteria for the classification of early systemic sclerosis. , 2001, The Journal of rheumatology.

[40]  M. Storr,et al.  Autoantibody Profile in Progressive Systemic Sclerosis as Markers for Esophageal Involvement , 2001, Journal of clinical gastroenterology.

[41]  T. Medsger,et al.  Severe organ involvement in systemic sclerosis with diffuse scleroderma. , 2000, Arthritis and rheumatism.

[42]  R. Sjogren Gastrointestinal features of scleroderma. , 1996, Current opinion in rheumatology.

[43]  R. Sjogren,et al.  Gastrointestinal motility disorders in scleroderma. , 1994, Arthritis and rheumatism.

[44]  A. Silman,et al.  Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. , 1993, The Journal of rheumatology.

[45]  C. Sherbourne,et al.  The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .

[46]  A. Masi Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.

[47]  James F. Fries,et al.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. , 1980, Arthritis and rheumatism.

[48]  S. Guiducci,et al.  Evidence for oesophageal and anorectal involvement in very early systemic sclerosis (VEDOSS): report from a single VEDOSS/EUSTAR centre. , 2015, Annals of the rheumatic diseases.

[49]  D. Farge,et al.  Évaluation de la qualité de vie par le MOS-SF36 dans la sclérodermie systémique , 2004 .

[50]  P. Lachenbruch,et al.  The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. , 1998, The Journal of rheumatology.

[51]  Ware J.E.Jr.,et al.  THE MOS 36- ITEM SHORT FORM HEALTH SURVEY (SF- 36) CONCEPTUAL FRAMEWORK AND ITEM SELECTION , 1992 .

[52]  M. Camilleri,et al.  Abnormal postcibal antral and small bowel motility due to neuropathy or myopathy in systemic sclerosis. , 1989, Gastroenterology.